CSI Market
Sign In | Register

Sangamo Therapeutics Inc (SGMO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SGMO Annual Cash Flow →
Looking at cash flow data from Sangamo Therapeutics Inc through Mar 31 2025 provides insight into Mar 31 2026's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-31.00
Depreciation & amortization0.72
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.99
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Build To Suit Leases-
Gain On Free Shares-
Gain Loss On Termination Of Lease-
Increase Decrease In Contract With Customer Liability-0.50
Amortization And Other Changes In Right Of Use Assets-
Operating Lease Right Of Use Asset Amortization Expense0.16
Adjustment Of Award Liability-
Increase Decrease In Operating Lease Liability-0.45
Goodwill And Intangible Asset Impairment-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable4.65
Increase (Decrease) in Accounts Payable and Accrued Liabilities4.94
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.20
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-19.28
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities0.00
Payments for Leasing Costs0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Additional Interest in Subsidiaries0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock27.08
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-21.38
Proceeds From Issuance Initial Public Offering Net Of Costs-
Net Proceeds From Issuance Public Offering-
Proceeds From Claims Settlement-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents20.95
Capital Expenditures Incurred But Not Yet Paid0.06
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Minority Interest Decrease From Redemptions-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities26.70
Effect of exchange rate on cash flow-0.77
Discontinued operations0.00
Free Cash Flow-19.30
Total Cash Flow6.64
4 historic quarters locked

Sign in to unlock the full Sangamo Therapeutics Inc cash flow history.

Sign In Create Free Account

About Sangamo Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-035067

Figures are derived from filed reports and may be restated. Historical data is subject to revision.